A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment

Tsuyoshi Iwanaka1, Takayoshi Yamaza2*, Soichiro Sonoda2, Koichiro Yoshimaru1, Toshiharu Matsuura1, Haruyoshi Yamaza3, Shouichi Ohga4, Yoshinao Oda5 and Tomoaki Taguchi1

Abstract

Background: Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.

Methods: We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibroblast (CFU-F) method and expanded them under a xenogeneic-free and serum-free (XF/SF) condition; hDPSC products were subsequently stored by two-step banking including a master cell bank (MCB) and a working cell bank (WCB). The final products were directly thawed hDPSCs from the WCB. We tested the safety and quality check, stem cell properties, and preclinical potentials of final hDPSC products and hDPSC products in the MCB and WCB.

Results: We optimized manufacturing procedures to isolate and expand hDPSC products under a XF/SF culture condition and established the MCB and the WCB. The final hDPSC products and hDPSC products in the MCB and WCB were validated the safety and quality including population doubling ability, chromosome stability, microorganism safety, and stem cell properties including morphology, cell surface marker expression, and multipotency. We also evaluated the in vivo immunogenicity and tumorigenicity and validated in vivo therapeutic efficacy for liver regeneration in a CCl4-induced chronic liver fibrosis mouse model in the final hDPSC products and hDPSC products in the WCB.

(Continued on next page)
Conclusion: The manufacture and quality control results indicated that the present procedure could produce sufficient numbers of clinical-grade hDPSC products from a tiny deciduous dental pulp tissue to enhance clinical application of hDPSC products in chronic liver fibrosis.

Keywords: Human deciduous pulp stem cells (hDPSCs), Clinical-grade, Manufacturing, Validation, Chronic liver fibrosis

Background

Human mesenchymal stem cells (MSCs) were first identified as non-hematopoietic lineage cells in the bone marrow and exhibited plastic adherent colony formation, including fibroblast-shaped cells, colony-forming unit-fibroblast (CFU-F) [1]. Because of the therapeutic benefit including self-replication, survival, multi-differentiation, and immunomodulation [2–4], MSC-based therapy has become a feasible and promising option for various refractory diseases [5]; MSCs have been tested in several clinical trials [6–8]. Large-scale ex vivo growth and a steady supply of clinical-grade MSCs is required for the wide range of clinical applications in human MSC-based tissue engineering and regenerative medicine. However, the production of clinical-grade human MSCs for patient treatment cannot be achieved using the simple laboratory-scale procedure, including the isolation and expansion of MSC for basic and translational studies. The ex vivo standard procedure for clinical-grade MSCs should be employed to produce clinical-grade MSC products with a defined quality and safety as well as an ensured steady supply [9, 10]. To produce final products with a defined quality and safety that are clinically utilized for patients, a validated standard operating procedure (SOP) needs to be established for the whole manufacturing and quality control process to produce clinical-grade MSCs [11]. Recently, MSC products have been commercially approved for treating patients with refractory graft-versus-host disease (GVHD) in Korea, Canada, New Zealand, and Japan [12, 13].

Diverse congenital and acquired liver diseases, such as liver cirrhosis, metabolic liver diseases, and hepatic carcinomas, eventually result in end-stage hepatic disorders including fulminant hepatitis and liver failure. Orthotopic liver transplantation (OLT) is the only radical option to recover from end-stage liver conditions [14]. However, there are several problems with OLT, such as long-term waiting and shortage of donor organs, surgical injuries, organ rejection, life-long use of immunosuppressive drugs, and high medical costs, which burden patients with end-stage liver disorders [15]. On the other hand, human primary hepatocyte transplantation may be a considerable alternative to OLT [16, 17], but the shortage of effective donor hepatocytes limits the clinical benefit of primary hepatocyte transplantation [18], indicating that a novel alternative therapeutic is required for patients with end-stage liver disorders. Recently, MSC-based therapy was considered as a potential option for refractory liver disease and was subsequently introduced into clinical trials [19, 20].

Human MSCs isolated from dental pulp tissue of deciduous teeth represent a feasible candidate for future MSC-based therapies. The human deciduous pulp stem cells (hDPSCs) exhibit remarkable stem cell potency, including cell proliferation, mesenchymal multipotency, and immunosuppressive function, in comparison with bone marrow-derived MSCs [21, 22]. Moreover, current xenogeneic transplant studies in a variety of animal disease models have provided beneficial evidence of the usefulness of hDPSCs [22, 23]. More recently, clinical studies reported the therapeutic use of hDPSCs for dental pulp regeneration in injured teeth [24]. Therefore, given recent studies of in vitro hepaticogenic capacity [25] and the in vivo liver regenerative efficacy of hDPSCs [26], hDPSCs may offer a promising source with superior clinical efficacy and great clinical demand for treating liver diseases. However, it is unclear how to generate consistent, large-scale ex vivo clinical-grade hDPSCs using the current isolation and culture techniques. An incomplete understanding of the effectiveness of clinical-grade hDPSC products to treat liver disorders and the lack of a SOP to secure the quality and safety of clinical-grade hDPSCs remain to be addressed before introducing clinical-grade hDPSC products into clinical applications.

In this study, we established a practical and reliable procedure for the clinical-grade production of dental pulp stem cells from human deciduous teeth, hDPSCs, based on a CFU-F method. We optimized the manufacturing procedures to isolate, expand, and store clinical-grade hDPSC products under xenogeneic-free (XF) and serum-free (SF) (XF/SF) culture conditions. In addition, we evaluated the final clinical-grade hDPSC products, not only for in vitro quality and safety, but also for in vivo therapeutic efficacy for liver regeneration in a CCl4-induced chronic liver fibrosis mouse model to enhance clinical application of clinical-grade hDPSC products.

Materials and methods

Ethics statement and human subjects

Procedures for handling human samples were approved by the Kyushu University Institutional Review Board for
with the relevant guidelines and regulations. All methods were performed in accordance with the guidelines and regulations of the Institutional Animal Care and Use Committee of Kyushu University Hospital. All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Kyushu University (Protocol Number: A21-044-1). All methods were performed in accordance with the relevant guidelines and regulations.

Animals and cell lines
Wild-type C57BL/6J mice (male, 8 weeks old) were obtained from Charles River Laboratories Japan (Yokohama, Japan). The animals were maintained with free access to sterilized water and a standard chow MF diet (Oriental Yeast, Tokyo, Japan) under controlled environmental conditions with a 12-h light/12-h dark cycle. The human hepatoma-cell line HepG2 cells were provided from Riken BRC (Tsukuba, Japan) and were cultured according to the manufacturer’s instruction.

Isolation of hDPSCs under XF conditions
All extracted deciduous teeth used in this study were quickly stored in 20 mL of Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific, Waltham, MA) alone at 4 °C and were transported from the clinic to laboratory bench at 4 °C within 24 h before we start to isolate hDPSCs. Isolation of hDPSCs was performed under XF conditions by a colony-forming unit-fibroblast (CFU-F) method [1]. The deciduous pulp tissue of deciduous teeth was removed and was minced with a surgical blade, followed by digestion with 3 mL of the XF tissue digestion regent Liberase™ MNP-S (0.45 Wünsch units/mL; Roche, Basel, Switzerland) diluted in sterilized Ca²⁺- and Mg²⁺-free phosphate-buffered saline (PBS; Nacalai Tesque, Kyoto, Japan) at 37 °C for 30 min. Each digested suspension was passed through a 70-µm cell strainer (Corning, Corning, NY) into a 50-mL polystyrene tube (Corning) to obtain a single-cell suspension and was centrifuged at 770×g at 4 °C for 5 min in an Allegra® X-30R centrifuge machine (Beckman Coulter, Brea, CA) equipped with a SX4400 swinging rotor (Beckman Coulter). The single-cell suspension was seeded into a T-75 culture flask (Corning) with 10 mL of a MSC NutriStem® XF Medium (XFM; Biological Industries, Beit HaEmek, Israel) without antibiotics. Eighteen hours after the initial seeding, the culture flasks were washed twice with 1 mL of PBS (Nacalai Tesque) to remove floating cells and were further cultured for 10–14 days with 10 mL of XFM (Biological Industries). The cells were maintained at 37 °C with 5% CO₂ in a Forma™ CO₂ incubator (Thermo Fisher Scientific). Adherent colony formation was inspected daily and was confirmed using a Primovert inverted microscope (Carl Zeiss Microscopy, Jena, Germany).

Cell passage and expansion of hDPSC products
Cultured medium was removed, and the culture flasks were washed twice with 1 mL of PBS (Nacalai Tesque). The hDPSC products were removed from the flask using 1 mL of a cell removal reagent TrypLE™ select without phenol red (Thermo Fisher Scientific) at 37 °C for 5 min. The removed hDPSC products were collected by centrifugation, as described above, and the cell pellet was diluted in XFM (1 mL; Biological Industries). The hDPSC products (0.25 × 10⁶ per flask) were seeded in a new T-75 flask (Corning) with XFM (10 mL; Biological Industries). When they were 70% confluent, the hDPSC products were passaged again to expand as described above. The medium was exchanged twice a week. The cells were maintained at 37 °C with 5% CO₂ in a Forma™ CO₂ incubator (Thermo Fisher Scientific) and were inspected daily using a Primovert inverted microscope (Carl Zeiss Microscopy).

Cell counting of hDPSC products
A dye exclusion test with trypan blue (Bio-Rad Laboratories, Hercules, CA) was performed to determine the cell number. The number of the hDPSC products was counted with a TC20 cell counter (Bio-Rad Laboratories) using its counting slides (Bio-Rad Laboratories), according to the manufacturer’s instructions. The hDPSC products were counted in triplicate and the mean of the three measurements was adopted as the cell number.

Cell freezing and thawing of hDPSC products
The hDPSC products were washed with 1 mL of PBS (Nacalai Tesque) twice and were treated with 1 mL of

| Table 1 Summary of donor information |
|-------------------------------------|
| Donor | Sex | Age (years, months) | Tooth number | Medical history |
|-------|-----|---------------------|--------------|----------------|
| #1    | Male | 6y3m               | 11           | None           |
| #2    | Female | 6y11m              | 21           | None           |
| #3    | Male | 7y0m               | 11           | None           |
| #4    | Female | 7y3m               | 11           | None           |
| #5    | Male | 7y7m               | 11           | None           |
| #6    | Female | 6y10m              | 21           | None           |
| #7    | Female | 8y10m              | 21           | None           |
| #8    | Male | 7y4m               | 21           | None           |
| #9    | Male | 6y10m              | 11           | None           |
| #10   | Male | 7y8m               | 11           | None           |

Tooth numbers are determined by the Fédération Dentaire Internationale (FDI) tooth-numbering system.
TrypLE™ select without phenol red (Thermo Fisher Scientific) at 37°C for 5 min. The removed hDPSC products were mixed at a concentration of 1.0 × 10⁶/mL with a STEM CELL BANKER™ cryomedium (Zenoak, Fukushima, Japan), followed by storage in cryogenic vials (Sumitomo Bakelite, Tokyo, Japan). The vials were kept for 4 h at –80°C in a CoolCell™ LX ell freezing container (BioCision, Larkspur, CA) and then were packed in a cryogenic Nalgene® CryoBox™ System 100™ container (Thermo Fisher Scientific). Finally, the containers were stored in a LS6000 cryogenic refrigerator (Worthington, Columbus, OH) filled with liquid nitrogen.

The frozen hDPSC products were thawed with ThawSTAR™ CFT2 (Astero, Bothell, WA) and were transferred to a 15-mL polystyrene tube (Corning) containing 4 mL of XFM (Biological Industries). The cell pellet was obtained by centrifugation using the same conditions as described above. The supernatant was removed and the cell pellet was suspended in 1 mL of XFM (Biological Industries). The number of hDPSC products in the suspension was counted as described above, and the hDPSC products (0.25 × 10⁶ per flask) were seeded in a T-75 flask (Corning). The medium was exchanged twice a week.

**Adherent colony formation assay of hDPSCs**

Isolated cells (10 × 10⁶) from the deciduous dental pulp tissue were seeded into a 100-mm culture dish (Corning) and were cultured in 10 mL of XFM (Biological Industries) for 14 days. The culture dish was treated with 3 mL of 4% paraformaldehyde (Merck, Darmstadt, Germany) and 0.1% toluidine blue (Merck) in PBS (pH 7.4; Nacalai Tesque) for 18 h. After washing five times with 1 mL of PBS, the dish was air-dried and was imaged with a GT-X980 scanner (Epson, Suwa, Nagano). Numbers of CFU-F, which contained >50 cells, were counted using a Primovert inverted microscope (Carl Zeiss Microscopy).

**Population doubling (PD) assay of hDPSC products**

The P1 hDPSC products were sequentially passaged every 7 days under XF/SF conditions until they lost their dividing ability. The culture medium was changed every 3 days. The population doubling level (PDL) at each passage was calculated according to the equation: PDL = 3.32 (log [number of harvested cells at end of a passage] – log [number of seeded cells at initial of a passage]).

**Chromosomal analysis of hDPSC products**

Chromosomal analysis of the hDPSC products, including chromosome numbers and G-banded karyotypes, was performed with Giemsa staining by LSI Medience Corporation (Tokyo, Japan).

**Microorganism tests of hDPSC products**

Microorganism tests for endotoxin, Treponema, Mycoplasma, cytomegalovirus (CMV), hepatitis B virus (HBV), HCV, human immunodeficiency virus 1 (HIV-1), human T-cell leukemia virus type 1 (HTLV-1), and parvovirus were analyzed using the conditioned medium (CM) of the hDPSC products by LSI Medience Corporation (Tokyo, Japan).

**Characterization of hDPSC products**

Characterization of the hDPSC products was examined according to recent studies [21, 22, 27], as described in the Supplementary Methods. As for cell morphology assay, hDPSC products in a T-75 flask (Corning) were imaged under a Primovert inverted microscope (Carl Zeiss Microscopy). The expression of MSC surface markers including human CD146, CD105, CD73, CD90, CD34, CD45, CD14, and human leukocyte antigen DR (HLA-DR), which were referred from a previous report [28], in hDPSC products was examined by flow cytometric analysis (FCM). The lineage-specific-gene expression was analyzed in the hDPSC products cultured under the specific inductive conditions into osteoblasts, chondrocytes, and adipocytes by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay. For secretome assay, hepatocyte growth factor (HGF), interleukin 6 (IL6), monocyte chemotactic protein 1 (MCP1), and sialic acid-binding immunoglobulin-type lectin 9 (SIGLEC9) in the CM of the hDPSC products were analyzed by enzyme-linked immunosorbent assay (ELISA).

**Hepatogenic differentiation of hDPSC products**

Hepatogenic differentiation of the hDPSC products was induced according to a previously reported protocol [25] and analyzed by qRT-PCR assay, as described in the Supplementary Methods.

**Stanniocalcin 1 (STC1) expression in hDPSC products**

The hDPSC products were cultured according to a previously reported protocol [25]. Expression of STC1 was analyzed in hDPSCs by qRT-PCR assay, as described in the Supplementary Methods.

**In vitro tumorigenicity of hDPSCs**

The in vitro colony-forming ability of the hDPSC products was tested using a Cell Transformation Detection Assay (Merck) according to the manufacturer’s instructions. The hDPSC products (500 cells per well) were cultured in agar for 2 weeks, and the colony formation was analyzed under a Primovert microscope (Carl Zeiss). Telomerase activity in hDPSC products was tested using a telomerase repeat amplification protocol with a Telomerase PCR ELISA™ (Merck) according to the manufacturer’s instructions, as described in the
Supplementary Methods. Expression of MYC was analyzed in hDPSCs using qRT-PCR, as described in the Supplementary Methods. HepG2 cells were used as a positive control in all tests.

Immunogenicity of hDPSCs
Immunogenic markers including HLAs (HLA-ABC, HLA-E, HLA-DR, and HAL-DQ), T-cell cofactors (CD80, CD86, and CD40), and T-cell marker (CD3) in hDPSCs were analyzed by FCM. For T cell activity assay, a mixed culture experiment of the hDPSC products and human peripheral blood mononuclear cells (PBMNCs) was tested as in a previous report [22], as described in the Supplementary Methods.

Transplantation of hDPSC products into chronically CCl4-injured mice
Wild-type mice at 9 weeks of age intraperitoneally received a CCl4 solution twice a week for 4 weeks. The CCl4 solution was freshly prepared CCl4 (0.5 mg/kg in olive oil [Wako Pure Chemicals]; CCl4:olive oil = 1:4 volume/volume). The 4-week-CCl4-treated mice received each donor-derived hDPSC products (0.1 × 10^7/10 g body weight in PBS) via the spleen [26]. The hDPSC-transplanted mice were subsequently treated with CCl4. The age-matched mice that received olive oil and sham-operated CCl4 were used as negative and positive controls.

Histological and immunohistochemical analyses of mouse liver tissues
The paraffin sections of mouse livers were treated with Picrosirius Red staining [26]. Immunohistochemical analysis was also tested to determine the localization of HLA-ABC, human hepatocyte antigen paraffin 1 (HepPar1), human albumin, and mouse actin, alpha 2, smooth muscle (ACTA2), as described in the Supplementary Methods. Immunohistochemical controls were tested using non-immune antibodies. All sections were observed under a BZ X-700 microscope (KEYENCE, Tokyo, Japan).

Five immunohistochemical sections were randomly selected and were analyzed for the percentage of fibrous tissue area or primary antibody-positive area using ImageJ software (NIH, Bethesda, MD, USA). Picrosirius Red-stained sections were also analyzed to score the amount of liver damage using Ishak scoring [29].

Liver functional assays of mouse serum
Alanine aminotransferase (ALT), aspartate transferase (AST), and total bilirubin in mouse serum were measured by biochemical assays. Human albumin in mouse serum was analyzed by ELISA. Biochemical assays and ELISAs were performed as described in the Supplementary Methods.

Liver fibrosis assay of mouse liver tissues
Gene expression of mouse collagen type 1 alpha 1 (ColIa1) and Acta2 was tested by qRT-PCR, as described in the Supplementary Methods.

Statistical analysis
Statistical results are expressed as mean ± standard error of the mean (SEM) or mean ± standard deviation (SD). Multiple group comparisons were analyzed by one-way repeated-measures analysis of variance (ANOVA) followed by the Tukey post hoc test. Values of P < 0.05 were considered significant. All statistics were analyzed using JMP 11 (SAS Institute, Cary, NC).

Results
Establishment of a SOP for the manufacture and quality control of hDPSC production using CFU-F-derived multiclonies under XF conditions
The basic procedure of the present isolation and expansion of hDPSCs was similar to the original procedure [21, 22], but the difference was propagation to secure XF/SF conditions compared to the original procedure. We then optimized the laboratory-scale CFU-F protocol for large-scale expansion (Fig. 1). Remnant dental pulp tissues of deciduous teeth extracted from healthy donors were treated with a XF tissue digestion regent, and the single-cell suspension was seeded into a regular T-75 cm^2 plastic culture flask with a commercially available XF medium. Eighteen hours after the initial seeding, any floating cells were removed from the flask, and the attached cells on the bottom of the flask were maintained to form adherent colonies in XF/SF conditions. The whole colony-forming cells were collected from a flask and were re-plated into a T-75 cm^2 flask at a seeding density of 0.25 × 10^6 per T-75 cm^2 flask as P1. In the present SOP, for the cell expansion process, T-75 cm^2 flasks were used and the seeding number was 0.25 × 10^6 per T-75 cm^2 flask at each passage. Cell passage was performed every 7 days. Cell storage steps for the master cell bank (MCB) and the working cell bank (WCB) were added to the present manufacturing process. Lastly, the final hDPSC products for patients were cataloged to provide a directory of the hDPSC products stored in WCB.

In the present SOP, several assurances for the quality, safety, and efficacy of hDPSC products were validated at each step, including the MCB, the WCB, and the final products. In the present procedure, the basic criteria included the total PDL 20, chromosomal stability, and microorganism safety and were measured for the WCB. To determine the timing for the WCB by the PDL 20 threshold, hDPSC products were prepared for a sequential passage. In the process of the sequential passage, the P3 hDPSC products were stored in the MCB to maintain the cells with the significantly high proliferation potential at
an early stage for future manufacturing. If hDPSC products for the WCB storage failed to meet any of the basic criteria, they were discarded immediately. Only the hDPSC products that passed the basic criteria for the WCB, as well as the P3 hDPSC products for MCB, were employed to test further MSC criteria including cell morphology, surface marker analysis, and multipotency. The hDPSC products in the MCB and the WCB storages must meet all prerequisite criteria. If the cells failed to meet any of the criteria, they were discarded immediately. Moreover, the hDPSC products for the WCB storage were used for additional tests on the in vitro immunogenicity and tumorigenicity and were also tested in an in vitro hepatogenic capacity. The quality tests of the final hDPSC products were cell viability, MSC marker analysis, and microorganism tests. In vivo preclinical tests were also carried out to determine the therapeutic efficacy of the final hDPSC products, as well as hDPSC products in the WCB, in a chronic liver fibrosis mouse model.

Primary validation of hDPSC products for MCB and WCB products
We randomly selected ten different healthy pediatric donors, who were clinically diagnosed as healthy without...
any systemic disease (Table 1). The tooth samples were transport from a clinic to our laboratory at 4 °C within 24 h before we start to isolate hDPSCs. Their hDPSCs were successfully able to form attached colonies containing spindle-shaped cells on the plastic culture flasks (Fig. 2a, b).

We produced the P3 hDPSC products from the colony-forming hDPSCs and stored them in liquid nitrogen for the MCB. We then subjected some cryopreserved P3 MCB products to a population doubling assay. The hDPSC products were sequentially passed every 7 days until they lost their proliferative capacity. All ten donor-derived hDPSC products commonly exhibited a limited capacity of cell proliferation (Fig. 2c, Supplementary Table 1). Only donor #3-derived hDPSC products stopped its growth at P7 with a PDL of 9.7. The other 9 donor-derived hDPSC products exceeded a PDL of 26, and the P10 hDPSC products showed a PDL of 20, indicating that the donor #3-derived hDPSC products were excluded to prepare for the WCB batch (Fig. 1).

In parallel, we tested the chromosomal stability and microorganism safety of the nine donor-derived P10 hDPSC products for the WCB. A chromosomal aberration was detected in the donor #8- and #9-derived P10 hDPSC products, but not in the other six donor-derived P10 hDPSC products (Table 2, Fig. 2d). Pathogenic
microorganism contamination was not detected in all P10 hDPSC products (Table 3). All P3 hDPSC products for the MCB also passed both tests (Tables 2 and 3). These findings indicated that donor #3–, #8–, and #9-derived hDPSC products did not pass the present basic criteria; therefore, the other seven donor (donor #1, #2, #4–#7, and #10)-derived P10 hDPSC products were used for further validation for the WCB.

Validation of the properties of hDPSC products for the MCB and the WCB

Characterization of P3 and P10 hDPSC products

We tested the properties of the ten donor P3 and seven donor (donor #1, #2, #4–#7, and #10)-derived P10 hDPSC products, which passed the present basic criteria, based on four criteria including cell morphology, cell surface marker expression, multi-differentiation potential, and immunosuppressive factor release. All P3 and P10 hDPSC products adhered on plastic culture dishes and showed a typical fibroblast-like morphology (Figs. 3a and 4a). A flow cytometric analysis showed that all P3 and P10 hDPSC products expressed MSC markers including CD105, CD73, and CD90 (Figs. 3b and 4b, Supplementary Figs. 1 and 2, Supplementary Table 2). Meanwhile, both P3 and P10 hDPSC products commonly lacked the expression of hematopoietic cell markers including CD34, CD45, and CD14, and HLA class II HLA-DR (Figs. 3b and 4b, Supplementary Figs. 1, 2, Supplementary Table 2). A multi-differentiation test demonstrated that the both passage products were capable of differentiating into the typical mesenchymal 3-lineage cells, as indicated by the expression of lineage-specific genes for osteoblasts (*RUNX2*, *ALP*, and *BGLAP*), chondrocytes (*SOX9*, *COL2*, and *COL10*), and adipocytes (*PPARG* and *LPL*) by qRT-PCR assay (Figs. 3c and 4c). An ELISA showed the ability to secrete anti-inflammatory factors including HGF, IL6, MCP1, and SIGLEC9 in the CM of the P3 and P10 hDPSC products (Figs. 3d and 4d). Our results presented no significant difference as MSCs including hDPSCs between P3 and P10 hDPSC products from donor #1, #2, #4–#10, indicating that donor #1, #2, #4–#10-derived P10 hDPSC products maintain the minimum requirement to establish working cell bank for MSCs including hDPSCs.

Tumorigenicity and immunogenicity of P10 hDPSC products

We additionally investigated the tumorigenicity and immunogenicity of the seven donor-derived P10 hDPSC products for the WCB, which passed both the basic and MSC criteria. A colony formation assay with a soft agar culture system indicated that all P10 cell products were not able to form cell clusters compared to the human liver cancer cell line HepG2 (Fig. 5a). Telomerase activity and qRT-PCR assays revealed that all P10 hDPSC products expressed significantly low levels of telomerase activity and MYC in comparison with HepG2 cells (Fig. 5b, c). A flow cytometric analysis showed that all seven donor-derived P10 hDPSC products lacked the expression of HLA class II antigens HLA-DR and HLA-DQ, T-cell cofactors CD80, CD86, and CD40, and T-cell marker CD3 (Figs. 5d, Supplementary Fig. 3). While, the intact P10-hDPSC products expressed HLA class I HLA-ABC, but not the class I antigen HLA-G (Figs. 5d, Supplementary Fig. 3). A mixed lymphocyte culture test determined that all P10 hDPSC products did not stimulate the cell viability of phytohemagglutinin activated allogenic PBMNCs (Fig. 5e).

Preclinical evaluation of P10 hDPSC products

An in vivo therapeutic efficacy test for chronic liver disease was conducted in the seven donor-derived P10 hDPSC products. The seven-donor-derived P10 hDPSC products under a hepatogenic culture protocol showed differentiation into hepatocyte-like cells, as indicated by expression of hepatocyte-specific genes by qRT-PCR assay (Fig. 6a). STC1 was secreted from MSCs during anti-oxidative stress in vitro and during an anti-fibrotic
The P10 hDPSC products expressed a marked expression of STC1 under hydrogen peroxide treatment (Fig. 6b), indicating that P10 hDPSC products might be a clinically promising product to regenerate damaged liver. Prior to the validation of P10 hDPSC products, we examined therapeutic effects of the P10 hDPSC-products in chronically CCl4-injured immunocompetent BL/6 mice. We evaluated that all donor-derived P3 hDPSCs-products recovered liver function in recipient chronically CCl4-injured BL/6 mice as indicated by the significant reduction of AST, ALT, and total bilirubin in the serum detection of human albumin in the serum (Supplementary Fig. 4). Next, the P10 hDPSC products were transplanted into chronically CCl4-injured immunocompetent BL/6 mice via the spleen without any immunosuppressant before or after the transplantation. An immunohistochemical assay using anti-HLA-ABC and anti-HepPar1 antibodies confirmed direct liver regeneration by the in situ transformation of the transplanted P10 hDPSC products (Fig. 7a–d). Biochemical assays revealed that the P10 hDPSC transplantation recovered damaged liver functions as indicated by a significant reduction of AST, ALT, and total bilirubin in the serum of the P10 hDPSC-transplanted group (Fig. 7e–g) and detection of human albumin in the serum of the P10 hDPSC-transplanted group (Fig. 7h). Interestingly, there was no significant difference in the effects on AST, ALT, total bilirubin, and human albumin in serum between P3 and P10 hDPSC products in the present chronic liver fibrosis. The P10 hDPSC transplantation decreased the activation of hepatic stellate cells as indicated by the decreased immunoreactivity for ACTA2 and the reduced gene expression of Acta2 in the CCl4-induced fibrous liver tissue by qRT-PCR and immunohistochemical analyses (Fig. 8a–c). The P10 hDPSC transplantation improved CCl4-induced liver fibrosis as indicated by the markedly suppressed area of fibrous tissue-deposition

| Donor   | Endotoxin (EU) | FTA-ABS | Mycoplasma | HCV | HBV | HTLV-1 | Parvovirus | CMV | HIV-1 |
|---------|----------------|---------|------------|-----|-----|--------|------------|------|-------|
| P3      |                |         |            |     |     |        |            |      |       |
| #1      | 0.025          | –       | –          | –   | –   | –      | –          | –    | –     |
| #2      | 0.021          | –       | –          | –   | –   | –      | –          | –    | –     |
| #3      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #4      | 0.022          | –       | –          | –   | –   | –      | –          | –    | –     |
| #5      | 0.025          | –       | –          | –   | –   | –      | –          | –    | –     |
| #6      | 0.027          | –       | –          | –   | –   | –      | –          | –    | –     |
| #7      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #8      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #9      | 0.022          | –       | –          | –   | –   | –      | –          | –    | –     |
| #10     | 0.025          | –       | –          | –   | –   | –      | –          | –    | –     |
| P10     |                |         |            |     |     |        |            |      |       |
| #1      | 0.024          | –       | –          | –   | –   | –      | –          | –    | –     |
| #2      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #3      | N/A            | N/A     | N/A        | N/A | N/A | N/A    | N/A        | N/A  | N/A   |
| #4      | 0.026          | –       | –          | –   | –   | –      | –          | –    | –     |
| #5      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #6      | 0.025          | –       | –          | –   | –   | –      | –          | –    | –     |
| #7      | 0.024          | –       | –          | –   | –   | –      | –          | –    | –     |
| #8      | 0.025          | –       | –          | –   | –   | –      | –          | –    | –     |
| #9      | 0.021          | –       | –          | –   | –   | –      | –          | –    | –     |
| #10     | 0.027          | –       | –          | –   | –   | –      | –          | –    | –     |
| Thawed-P10 |            |         |            |     |     |        |            |      |       |
| #2      | 0.023          | –       | –          | –   | –   | –      | –          | –    | –     |
| #10     | 0.024          | –       | –          | –   | –   | –      | –          | –    | –     |
and the degree and expression of Col1a1 in the P10 hDPSC-transplanted group by Picrosirius Red staining, Ishak scoring, and qRT-PCR (Fig. 8d–g). Moreover, we further found that the P10 hDPSC transplantation reduced liver fibrotic-related genes and proteins including metalloproteinases 2 (Mmp2), Mmp3, inhibitor of metalloproteinase 1 (Timp1), Timp2, and transforming growth factor beta in the CCl4-induced mouse fibrous liver tissue by qRT-PCR analysis and ELISA (Supplementary Fig. 5). These findings suggested that the P10 hDPSC products were a feasible therapeutic option for chronic liver fibrosis.

Validation of final hDPSC products for chronic liver fibrosis treatment

Colony number is a relatively easy and early evaluation means in the cell manufacturing process. In this study, we divided donors into two groups; donors #2, #3, #6, #7, and #8 were a low colony-forming ability group, and the other donors #1, #4, #5, #9, and #10 were a high colony-forming
ability group. We then randomly selected donors #2 and #10 from each group and used as the final hDPSC products for clinical validation to assess whether colony-forming ability of donors can determine the therapeutic efficacy of hDPSCs. The mean viability of the two donor-derived final hDPSC products after thawing was 73.4 ± 4.5% and 69.8 ± 7.2%, respectively, while the pre-cyropreserved viability was 91.4 ± 3.9% and 89.8 ± 4.1%, respectively (Fig. 9a). From the results of cell surface antigen expression by flow cytometric analysis, the two clinical hDPSC products were evaluated for their MSC immunophenotype and less immunogenicity (Fig. 9b, c, Supplementary Fig. 6, Supplementary Tables 2, 3). Microorganism tests confirmed no contamination with pathogens (Table 3). Furthermore, transplantation of the two final hDPSC products evaluated the therapeutic efficacy of liver regeneration via direct in situ transformation and antifibrotic effects in a CCl4-induced mouse model of liver fibrosis by biochemical and immunological serum assays, immunohistochemical analyses, Picrosirius Red staining, and Ishak scoring (Fig. 9d–g, Supplementary Fig. 7). However, there was no significant therapeutic difference between the two final products.

**Discussion**

In this study, we established a SOP for manufacturing clinical-grade hDPSC products from CFU-F-derived...
multi-colonies under XF/SF condition and built a two-step cryopreservation system including an MCB and a WCB in the procedure. The MCB was the first storage step for hDPSC products with high proliferation potential. The hDPSC products cryopreserved in the MCB were passaged and expanded to storage in the WCB, which would directly supply large numbers of the final hDPSC products to patients off-the-shelf. We then employed basic criteria including a PDL of 20, chromosomal stability, and microorganism safety, to manufacture

![Image](image_url)

Fig. 5 Tumorigenesis and immunogenicity of P10 hDPSC products. a Tumorigenicity of the P10 hDPSCs was performed by colony-forming assay in soft agar. The results are shown as representative microscopic images 12 weeks after culture. b Telomerase (Telom) activity in the P10 hDPSCs was analyzed by the telomeric repeat amplification protocol. The results are shown as the average activity of relative telomerase activity (RTA). c Expression of MYC in the P10 hDPSC products was analyzed by qRT-PCR. The results are calculated as the ratios of the expression of 18S ribosomal RNA (18S) and are shown as the average ratio. d Immunogenic antigens in the P10 hDPSCs were analyzed by flow cytometry. The results are shown as the average positive rates of each marker. HLA, human leukocyte antigen. e The in vitro immunogenic reaction of the P10 hDPSCs was analyzed using a mixed lymphocyte reaction test. Peripheral blood mononuclear cells (PBMCs) were mixed with gamma-irradiated hDPSCs and allogenic PBMCs (Allo-PBMCs), and its viability was measured at 450 nm (A450 nm). Phytohemagglutinin (PHA) was used as a T cell mitogen. The results are shown as the average viability. a–e N/A, not applicable. a–c HepG2, HepG2 cells are used as a positive control. b–e n = 3 for all groups. The graph bars show the mean (black columns) or mean ± SEM (gray columns). **P < 0.005. ns, not significant
enough numbers of safety products for the WCB. In the present study, we tested ten donor-derived hDPSC products whether each product meets the basic criteria. Finally, the seven donor-derived hDPSC products for the WCB products were obtained. The three donor-derived hDPSC products did not meet our basic criteria; one donor-derived hDPSC product showed very low population doubling ability, and the others showed chromosomal abnormalities in the WCB. All seven donor-derived hDPSC products fulfilled the stem cell properties including morphology, immunophenotype, multipotency, and immunosuppressive function. They also showed the preclinical criteria including low immunogenicity, less tumorigenicity, hepaticogenic capacity, and in vivo therapeutic efficacy in a liver fibrosis mouse model. Moreover, randomly selected two donor-derived final hDPSC products were verified the clinical safety and applicability for treating chronic liver fibrosis, suggesting that the present SOP, for the first time, provides a manufacturing of clinical-grade hDPSC products for treating chronic liver fibrosis.

Heterogeneous serum such as fetal bovine serum (FBS) has been generally used as an essential source of growth factors and other components to isolate and expand hDPSCs in vitro [21, 22, 26]. The use of FBS involves many safety concerns for clinical application. FBS potentially contains pathogens such as mycoplasmas, prions, or viruses, resulting in immune/allergic reactions to the host. Animal-derived proteins and peptides in FBC are internalized into MSCs during in vitro expansion, resulting in the rejection of donor cells [30–32]. Substantial batch-to-batch variation of FBS is also a disadvantage to the large quantities [31, 33]. Meanwhile, homogeneous serum including human serum and human platelet lysate is proposed as an alternative to FBS and has demonstrated efficient support of cell proliferation of MSCs [34, 35]. The significant variation and limited supply of them may indicate the unsuitability in a large-scale manufacturing of MSCs [36]. XF/SF materials have been known to be more practical in the large-scale manufacturing of MSCs without the aforementioned safety concerns [35, 37]. Therefore, the present findings indicate that the present established XF/SF SOP might be a practical and robust procedure for manufacturing large amounts of clinical-grade hDPSC products.

Several passages, long-term expansion, and large-scale banking are required to manufacture enough numbers of clinical-grade hDPSC products. Recent clinical trials including a Phase II/III trial for acute graft versus host disease (GVHD) and a Phase I/II trial for pediatric metabolic liver diseases show approximately $1 \times 10^9$ cells per patient as the prospected clinical dose of MSCs [38, 39]. Since we can obtain at least $1 \times 10^9$ cells from one

---

**Fig. 6** Hepatogenic capacity of P10 hDPSC products for the WCB. **a** The hepatogenic capacity of the P10 hDPSCs was tested by hepatocyte-specific gene expression 4 weeks after hepatogenic inductive culture by qRT-PCR assay. The results are shown as the ratios of the expression of 18S and are shown as the average ratio. *AFP*, alpha fetoprotein gene; *ALB*, albumin gene; *ARG2*, arginase 2 gene; *ASL*, argininosuccinate lyase gene; *ASS1*, argininosuccinate synthase 1 gene; *ATP7B*, ATPase copper transporting beta gene; *CPS1*, carbamoyl-phosphate synthase 1 gene; *CYP3A4*, cytochrome P450 family 3 subfamily A member 7 gene; *FAH*, fumarylacetoacetate hydrolase gene; *KRT18*, keratin 18 gene; *NAGS*, N-acetylglutamate synthase gene; *TF*, transferrin gene; *TTR*, transthyretin. N/A, not applicable. The graph bars show the mean. **b** The P10 hDPSCs were stimulated with and without H$_2$O$_2$ to analyze the expression of stanniocalcin 1 (STC1) by qRT-PCR. The results are calculated as the ratios of the expression of 18S and are shown as the average ratio. **a**, **b** $n = 3$ for all groups. N/A, not applicable.
deciduous tooth (generally 2–3 × 10^6 cells from one deciduous tooth) from CFU-F colony-forming P0 cells with a doubling capacity of 20, we could prepare approximately 10,000,000 WCB units containing 1 × 10^6 clinical-grade hDPSC products per unit, resulting in a therapeutic option for 1000–10,000 patients. Therefore, the present PDL threshold 20 in clinical-grade hDPSC products is a reasonable criterion to secure the supply of the hDPSC products to patients.

Clinical-grade human MSC products should meet critical requirements including normal genetic karyotype and chromosomal stability during long-term culturing and after cryopreserved cell banking [40, 41]. Human MSCs have been considered to be relatively genetically
stable during culturing in vitro [42–48]. On the contrary, abundant recent studies have revealed that human MSCs exhibited spontaneous genomic alternation with increased passage number [49–54]. Previous chromosomal profiling studies also provide that karyotypic abnormalities and chromosomal instability in early passaged human MSCs disappear during the extended passage [51, 54–56]. A study further reports that ten batched

---

**Fig. 8** Transplantation of P10 hDPSC products improves CCl4-induced liver fibrosis in mice. Each donor-derived P10 hDPSC products were intrasplenically transplanted into 4-week-CCl4-treated immunocompetent mice without immunosuppressants (n = 5). The age-matched control non-CCl4-treated (n = 5) and non-transplanted CCl4-treated (n = 5) immunocompetent mice were used as experimental controls. a–c Expression of the activated stellate cells in the CCl4-damaged fibrotic liver tissues was investigated. Representative immunohistochemical images show the distribution of actin alpha 2 smooth muscle, aorta (ACTA2) in mouse liver tissue. Nuclei were stained with hematoxylin. Bars = 50 μm (a). The area of ACTA2-positive cells in mouse liver tissue was analyzed (b). The expression of the Acta2 was investigated by qRT-PCR (c). d–f Deposition of fibrous tissues in CCl4-damaged liver tissues was investigated. Representative histological images show the distribution of fibrous tissue in mouse liver tissue by picrosirius red staining. Bars = 50 μm (d). The picrosirius red-positive area in mouse liver tissue was analyzed (e). The expression of the collagen type I alpha 1 chain gene (Col1a1) was investigated by qRT-PCR. The results are shown as the ratios of the expression of 18S (f). The liver fibrosis stages were assessed by Ishak scoring (g). a–g n = 5 for all groups. *P < 0.05, ***P < 0.005. The graph bars show the mean ± SEM (white columns) or the mean (black columns). ns, not significant.
Fig. 9 Transplantation of final hDPSC products from WCB improves CCl₄-induced pro-fibrotic markers in mice. Two cryopreserved hDPSC products in WCB (donor #2 and #10) were randomly selected from the WCB batch and were thawed to use as final hDPSC products for the quality check. a Cell viability of the final hDPSC products. The final hDPSC products thawed from 10 vials. They were stained with trypan blue, and living cells were counted. Black columns, living cell numbers of the final hDPSC products at freezing; White columns, living cell number of the final hDPSC products after thawing. The graph bars show the mean ± SEM. n = 10. b, c Cell surface marker analysis of the final hDPSC products was tested by flow cytometric assay. Markers for mesenchymal stem cells (b) and immunogenic antigen (c) were assessed in the final hDPSC products. The results were shown as the averaged positive rates of each marker in each donor. n = 3. d-f Each final hDPSC products were intrasplenically transplanted into 4-week-CCl₄-treated immunocompetent mice without immunosuppressants (n = 5). The age-matched control non-CCl₄-treated (n = 5) and non-transplanted CCl₄-treated (n = 5) immunocompetent mice were used as experimental controls. Serum levels of AST, ALT, total bilirubin (d), and human ALB (e) were examined by biochemical assays and ELISA. Distribution of the donor cells and deposition of fibrous tissues in the CCl₄-damaged fibrotic liver tissues was investigated by immunohistochemical assay and collagen staining. The results are shown as representative images stained with antibodies against HLA-ABC, HepPar1, ACTA2, and Picrosirius Red. Nuclei are stained with hematoxylin. Bars = 50 μm (f). The liver fibrosis stages were assessed by Ishak scoring (g). d, e, h n = 5 for all groups. *P < 0.05, ***P < 0.005. The graph bars show the mean ± SEM (black columns) or the mean (white columns). ns, not significant.
clinical-grade human MSC products not only occur 20% of non-random chromosomal abnormality, but also recur the abnormality in multiple products from the same batch [57]. In this study, we revealed karyotype abnormality in two hDPSC products for the WCB, but not for the MCB. Meanwhile, the abnormal hDPSC products for the WCB exhibited no tumorigenicity and showed no difference of the stem cell properties and therapeutic efficacy when compared to the normal hDPSC products for the WCB (data not shown). Heterogeneity of dental stem cells plays a crucial role in the genetic stability to suppress tumorigenesis and differentiation capacity [58]. These findings suggest that the quality and type of chromosomal abnormality may occur in hDPSC products in a donor-dependent manner in an ex vivo cell processing. Further studies will be necessary to evaluate the significance and mechanism of chromosomal alternations and their associating therapeutic safety of hDPSC products.

Long-term manufacturing of clinical-grade MSCs in vitro may incur chromosomal aberrations and microorganism concerns [59, 60], indicating that the preliminary sorting of chromosomal stability and microorganism contamination in hDPSC products for the MCB and the WCB is essential and critical safety steps required for obtaining clinical applications the final hDPSC products. The present microorganism tests in hDPSC products are a reasonable verification of microorganism safety. The present chromosomal safety was validated only with G-band karyotyping in hDPSC products. G-band karyotyping is a classical, useful, and short chromosomal analysis, but fails to detect cryptic rearrangements or aberrations covering small areas, indicating that additional chromosomal tests are required. A parallel chromosomal assay using advanced cytogenetic techniques such as spectral karyotyping by fluorescent in situ hybridization and comparative genomic hybridization array may supply a more sophisticated evaluation of genetic stability in clinical-grade hDPSC products [54].

The present manufacturing and quality tests indicate the safe and sufficient production of clinical-grade hDPSC products for treating chronic liver fibrosis. However, several difficulties remain to meet good manufacturing practice (GMP) in the present procedure for clinical-grade hDPSC products. In particular, the present study lacked in vivo toxicological validation of clinical-grade hDPSC products. The further toxicity test should be designed to validate the quality and reproducibility regarding the safety of clinical-grade MSC products in animals to support the safety claim in patients.

**Conclusion**

In this study, we established a XF/SF-conditioned procedure for the clinical-grade production of hDPSCs from multiple CFU-F colonies. We built in a two-step cell banking system, the MCB and the WCB, and obtained final hDPSC products. Because deciduous dental pulp tissue is an accessible and practical stem cell source for research and therapy, the present manufacture, validation, characterization, and preclinical results indicate that the present manufacturing procedure will provide clinically feasible hDPSC products to treat chronic liver fibrosis.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01630-w.

**Abbreviations**

ACTA2: Actin, alpha 2, smooth muscle; Acta2: Actin, alpha 2, smooth muscle gene; ALT: Alanine aminotransferase; AST: Aspartate transferase; CFU-F: Colony-forming unit-fibroblast; CM: Conditioned medium; CMV: Cytomegalovirus; Col1a1: Collagen type I alpha 1 gene; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; FCM: Flow cytometry; GMP: Good manufacturing practice; GvHD: Graft-versus-host disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; hDPSCs: Human deciduous pulp stem cells; HepPar1: Human hepatocyte antigen paraffin 1; HGF: Hepatocyte growth factor; HIV-1: Human immunodeficiency virus type 1; HLA-ABC: Human leukocyte antigen A, B, and C; HLA-DQ: Human leukocyte antigen DQ; HLA-DR: Human leukocyte antigen DR; HLA-E: Human leukocyte antigen E; HTLV-1: Human T-cell leukemia virus type 1; IL6: Interleukin 6; MCB: Master cell bank; MCP1: Monocyte chemotactic protein 1; MMP2: Metalloproteinases 2 gene;
Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing. We also thank Ms. Tomoko Yamazaki (Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University) for her kind support of this study.

Authors’ contributions

T.I. and T.Y. contributed to the conception and design of the study; generation, collection, and assembly of data; interpretation of data; statistical analysis; and drafting of the manuscript; S.S., K.Y., T.M., H.Y., S.O., and Y.O. contributed to the generation, collection, and assembly of data and interpretation of data; T.T. contributed to the conception and design, interpretation of data, drafting of the manuscript, critical revision of the manuscript, and study supervision. All of the authors approved the final version of the manuscript. All the authors gave final approval and agreed to be accountable for all aspects of the work.

Funding

This work was supported by grants from the Japan Society for the Promotion of Science, including Grant-in-Aid for Scientific Research (KAKENHI) (grant number 16H02682, 17K11513, and 19K08598 to TT and 25293405 to TY).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate

Procedures using human samples were approved by the Kyushu University Institutional Review Board for Human Genome/Genome Research (Protocol Number: A21-044-1). We obtained written informed consent from the parents on behalf of the child donors. All animal experiments were approved by the Institutional Animal Care and Use Committee of Kyushu University (Protocol Number: A21-044-1).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Pediatric Surgery, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

2 Department of Molecular Cell Biology and Oral Anatomy, Kyushu University Graduate School of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

3 Department of Pediatric Dentistry, Kyushu University Graduate School of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

4 Department of Anatomic Pathology, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

5 Department of Anatomic Pathology, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Received: 23 October 2019 Revised: 30 January 2020 Accepted: 2 March 2020 Published online: 23 March 2020

References

1. Friedenstein AJ, Deriglosa UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92.

2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

3. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Saper-Cortonbach L, Marin FC, et al. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–5.

4. Bianco P, Robey PG, Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313–9.

5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726.

6. Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4:590–7.

7. Syková E, Rychmáčková P, Drahorádová I, Konrádová Š, Růžičková K, Volfířek I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/II clinical trial. Cell Transplant. 2017;26:620–6.

8. Mendes Filho D, Ribeiro PDC, Oliveira LF, de Paula DRM, Capuano V, de Assunção TSF, et al. Therapy with mesenchymal stem cells in Parkinson disease: history and perspectives. Neurologist. 2018;23:141–7.

9. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int. 2012;2012:652034.

10. Chase LG, Lakshminathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther. 2010;1(18).

11. Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet. 2008;17:R48.

12. Allison M. Gerzony backs Osiris, despite Prochymal flop. Nat Biotechnol. 2009;27:996.

13. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:284–33.

14. Sze YK, Dhawan A, Taylor RM, Bansal S, Mieli-Vergani G, Rela M, et al. Pediatric liver transplantation for metabolic liver disease: experience at King’s college hospital. Transplantation. 2009;87:87–93.

15. Murray R, J Redlich RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–32.

16. Dhawan A, Puppi J, Hughes RO, Mitry RR. Human hepatocyte transplantation: current experience and future challenge. Nat Rev Gastroenterol Hepatol. 2010;7:288–98.

17. Puppi J, Strom SC, Hughes RD, Bansal S, Castell JV, Dagher I, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 2012;21:1–10.

18. Hansel MC, Gramignoli R, Skvorak KJ, Dorko K, Marongiu F, Blake W, et al. The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients. Curr Protoc Toxicol. 2014;62:14.12.1–7.

19. Sakai Y, Takamura M, Seki A, Sunagozaka H, Terashima T, Komura T, et al. Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell. Regen Ther. 2017;6:52–8.

20. El-Ansary M, Abdel-Azz M, Mogawer S, Abdel-Hamid S, Hammon O, Teema S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Res. 2012;8:972–81.

21. Miura M, Grontos S, Zhao M, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003;100:5807–12.

22. Yamaza T, Kentaroh A, Chen C, Liu Y, Shi Y, Grontos S, et al. Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res Ther. 2010;1:15.

23. Sakai K, Yamamoto A, Matsubara K, Nakamura S, Naruse M, Yamagata M, et al. Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuroregenerative mechanisms. J Clin Invest. 2012;122:980–90.

24. Xuan K, Li B, Guo H, Sun W, Kou X, He X, et al. Decidual autologous tooth stromal cells regenerate dental pulp after implantation into injured teeth. Sci Transl Med. 2018;10:455.

25. Fujiyoshi J, Yamazaki H, Sonoda S, Yuninartha R, Iihara K, Nonaka K, et al. Therapeutic potential of hepatocyte-like cells converted from stem cells...
from human exfoliated deciduous teeth in fulminant Wilson’s disease. Sci Rep. 2019;9:1535.
26. Yamaza T, Matas FAS, Yuniartha R, Yamaza H, Fujiyoshi JK, Yanagi Y, et al. In vivo hepatogenic capacity and therapeutic potential of stem cells from human exfoliated deciduous teeth in liver fibrosis in mice. Stem Cell Res Ther. 2015;6:1–6.
27. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marin F, Kause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cell lines. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
28. Mendicino M, Bailey AM, Wonnacott K, Purri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14:141–5.
29. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22: 696–9.
30. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther J Am Soc Gene Ther. 2004;9:747–56.
31. Tekkkate C, Gunasingh GP, Cherian KM, Sankaranarayanan K. “Humanized” stem cell culture techniques: the animal serum controversy. Stem Cells Int. 2011;2011:504723.
32. Jin X, Xu Q, Champion K, Kruth HS. Endotoxin contamination of apolipoprotein A-I: effect on macrophage proliferation-a cautionary tale. Atherosclerosis. 2015;240:121–4.
33. Kamieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017;19:155–69.
34. Muraglia A, Nguyen VT, Nardini M, Mogini M, Covilli D, Dozin B, et al. Culture medium supplements derived from human platelet and plasma: cell commitment and proliferation support. Front Biosci Technol. 2017;5:566.
35. Brun J, Abruzzese T, Rolauffs B, Aicher WK, Hart ML. Choice of xenogenic-free expansion media significantly influences the myogenic differentiation potential of human bone marrow-derived mesenchymal stromal cells. Cytotherapy. 2016;18:344–59.
36. Mannello F, Tonti GA. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells. 2007;25:1603–9.
37. Wang Y, Wu H, Yang Z, Chi Y, Meng L, Mao A, et al. Human mesenchymal stem cells possess different biological characteristics but do not change their therapeutic potential when cultured in serum free medium. Stem Cell Res Ther. 2014;5:132.
38. Muru K, Miyamae K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–50.
39. Smets F, Dobbelaar D, McKiernan P, Dionisi-Vici C, Broué P, Jacquemin E, et al. Phase I/III trial of liver derived mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev. 2015;24:77–92.
40. Lange C, Caiorglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol. 2007;213:18–26.
41. Zhang ZX, Guan LX, Zhang K, Wang S, Cao PC, Wang YH, et al. Cyto genetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int. 2007;31:645–8.
42. Bochkov NP, Nikitina VA, Voronina ES, Kuleshov NP. Methodological guidelines for genetic safety testing of cell transplants. Bull Exp Biol Med. 2009;148:677–82.
43. Huang WW, Lai HH, Poon LS, Hui JK, Lee TK. Human mesenchymal stem cells: an FDA perspective. Cell Prolif. 2013;46:10–22.
44. Bogorodskaya M, Solarewicz MM, Vaz IM, Daga D, Rebelaio CL, Senegaglia AC, et al. Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif. 2013;46:10–22.
45. Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol. 2008;52:1033–42.
46. Redaelli S, Bentivegna A, Fouad M, Milosio M, Redondo J, Riva G, et al. From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2012;3:47.
47. Tarte K, Gaillard J, Lalatulle JJ, Foulillard L, Becker M, Mossafa H, et al. Chromosomal stability of mesenchymal stromal cells during in vitro culture. Cytotherapy. 2016;18:336–43.
48. Bochkov NP, Nikitina VA, Voronina ES, Kuleshov NP. Methodological guidelines for genetic safety testing of cell transplants. Bull Exp Biol Med. 2009;148:677–82.
49. Stultz BG, McGinnis K, Thompson EE, Lo Surdo JL, Bauer SR, Hursh DA. Chromosomal stability of mesenchymal stromal cells during in vitro culture. Cytotherapy. 2016;18:336–43.